Complications; Implant, Orthopedic, Infection or Inflammation
Conditions
Keywords
Articular Implant Infection
Brief summary
Articular Implant Infection (AII) is itself a complicated diagnosis and a challenging condition to treat. In elderly patients, the application of existing recommendations is impeded by multiple frailties For a better knowledge of the long-term consequences of AII in elderly patient, the investigators conduct a prospective, multicentric study, whitch aim this is to better evaluate the burden of AII on elderly patients, in terms of quality of life. Secondly, the investigators would like to identify the factors that influence the prognosis, in order to guide further prospective research.
Detailed description
Articular Implant Infection (AII) is itself a complicated diagnosis (diagnosis confirmation, pathogen identification, with appropriate samples) and a challenging condition to treat (long antibiotic exposure, repeated surgery, complex implant change). This condition requires a good cooperation between surgeon and infectious disease specialist, with a comprehension of each one's constraint. In elderly patients, the application of existing recommendations is impeded by multiple frailties (malnutrition, loss of autonomy, polypathology) which make each decision crucial. Indeed, from the choice of surgery to antibiotics management, all medical decision can induce more adverse events than in younger patients. For a better knowledge of the long-term consequences of AII in elderly patient, the investigators conduct a prospective, multicentric study, based on the evaluation of the EQ-5D-5L score during one year after AAI diagnosis in patients older than 75. The investigators evaluate this score and compare different groups of patients, according to age, nutrition status, Charlson comorbidity index, hospital stay length, and loss of autonomy, among others. The aim of this study is to better evaluate the burden of AII on elderly patients, in terms of quality of life. Secondly, the investigators would like to identify the factors that influence the prognosis, in order to guide further prospective research.
Interventions
OTHERaddition of two follow-up visits post infection
Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection. No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection
Sponsors
Centre Hospitalier Metropole Savoie
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* hospitalized in infectious diseases, surgery, post-emergency unit, or geriatrics, * diagnosed with a hip or knee prosthesis infection in the previous month according to the SPILF criteria (2009)(1).
Exclusion criteria
* Above criteria not met, * Patient refusal, * Mild cognitive impairment or more significant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the EQ-5D-5L quality of life score | 1 year | the EQ-5D-5L questionnaire is a European quality of life scale: a first part with questions called EQ-5D descriptive system comprising 5 items: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; each item is rated from 1 to 5; 1 corresponding to no problem, 5 representing extreme problems or total disability Changes in the EQ-5D-5L quality of life score, 1 year after the onset of symptoms will be evaluated |
| Changes in the EQ-5D-VAS assessing the patient's general condition, completed by the patient | 1 year | the EQ-5D-5L questionnaire is completed by a visual analogue scale, called EQ-5D VAS; it consists of a 20 cm line, graduated from 0 to 100, where the patient has to indicate how he/she evaluates his/her current state of health, 0 being the worst possible state and 100 the best; Changes in the EQ-5D VAS wil be evaluated 1 year after the onset of symptoms. |
Countries
France
Outcome results
None listed